CRA was observed to prevent cellular damage and maintain tissue homeostasis via restricting class I and II HDAC thus activating NRF2 in the prostate cancer (Chen et al., 2012; Yang et al., 2018a). This evidence concerns the gene HDAC9 and prostate carcinoma.